“Clinical trials are often slow, costly, and difficult to manage, especially in fast-evolving medical landscapes,” said , Co-Founder of ByteBrain. “MEDRAIL helps organizations react to safety data faster, reduce manual errors, and stay compliant with global regulatory standards.”

MEDRAIL uses a team of specialized AI agents, each trained to handle tasks like patient recruitment, protocol monitoring, safety surveillance, and documentation compliance. These agents work together in real time, adjusting to trial data and new regulatory guidelines as they emerge.

Priyanshi Bhatnagar, co-founder of ByteBrain

“What makes MEDRAIL unique is its built-in safety verification and explainability,” added , Co-Founder. “Every protocol change, every recommendation, it's backed by formal logic, transparent reasoning, and a full audit trail.”

Clinical trials can cost up to $3 billion per approved drug and take more than a decade to complete. ByteBrain believes that smarter, AI-assisted trial systems can cut that time significantly, potentially saving millions and accelerating time-to-market for life-saving therapies.

The platform was developed with input from clinical research experts across pharma, academic medical centers, and regulatory affairs. Initial feedback has been positive, with ByteBrain preparing to release technical papers and pilot studies in the coming months.

About ByteBrain

ByteBrain LLC is a research-first AI company specializing in complex, regulated industries. Based in the U.S., it combines consulting services with the development of advanced IP in healthcare, finance, and enterprise AI systems. MEDRAIL is the firm’s flagship healthtech innovation and part of its broader mission to build human-centered, compliance-ready AI solutions.